CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Kymera Therapeutics, Inc. - KYMR CFD

29.08
5.31%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.13
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 30.71
Open* 30.3
1-Year Change* 4.12%
Day's Range* 28.45 - 28.45
52 wk Range 13.15-66.45
Average Volume (10 days) 0.62225
Average Volume (3 months) 13.8196
Market Cap 1536.76
P/E Ratio N/A
Shares Outstanding 54864700
Revenue 45.962
EPS -2.93545
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Feb 22, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 2, 2022 30.71 2.82 10.11% 27.89 30.96 27.88
Dec 1, 2022 28.68 0.96 3.46% 27.72 29.00 27.72
Nov 30, 2022 28.92 0.93 3.32% 27.99 29.09 27.77
Nov 29, 2022 28.24 1.22 4.52% 27.02 28.27 27.01
Nov 28, 2022 27.30 -0.32 -1.16% 27.62 28.20 27.07
Nov 25, 2022 27.73 0.89 3.32% 26.84 27.94 26.47
Nov 23, 2022 27.19 -0.52 -1.88% 27.71 28.26 27.07
Nov 22, 2022 27.94 0.06 0.22% 27.88 29.55 27.22
Nov 21, 2022 28.77 0.23 0.81% 28.54 29.21 28.14
Nov 18, 2022 28.71 0.45 1.59% 28.26 28.87 27.54
Nov 17, 2022 27.89 -0.58 -2.04% 28.47 28.63 27.18
Nov 16, 2022 29.10 0.46 1.61% 28.64 30.15 28.64
Nov 15, 2022 29.97 0.64 2.18% 29.33 30.58 28.69
Nov 14, 2022 28.99 -0.93 -3.11% 29.92 30.31 28.86
Nov 11, 2022 30.84 1.59 5.44% 29.25 32.78 29.25
Nov 10, 2022 30.54 1.00 3.39% 29.54 30.95 29.05
Nov 9, 2022 27.81 -1.58 -5.38% 29.39 30.05 27.63
Nov 8, 2022 30.24 1.17 4.02% 29.07 30.91 28.23
Nov 7, 2022 29.01 -1.43 -4.70% 30.44 30.44 28.58
Nov 4, 2022 30.83 -0.27 -0.87% 31.10 32.45 29.88

Kymera Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2018 2019 2020 2021
Total revenue 0 2.934 34.034 72.832
Revenue 0 2.934 34.034 72.832
Total Operating Expense 21.451 45.139 80.338 173.362
Selling/General/Admin. Expenses, Total 3.772 7.981 18.233 36.345
Research & Development 17.679 37.158 62.105 137.017
Operating Income -21.451 -42.205 -46.304 -100.53
Interest Income (Expense), Net Non-Operating -0.016 0.959 0.711 0.313
Net Income Before Taxes -21.467 -41.246 -45.593 -100.217
Net Income After Taxes -21.467 -41.246 -45.593 -100.217
Net Income Before Extra. Items -21.467 -41.246 -45.593 -100.217
Net Income -21.467 -41.246 -45.593 -100.217
Income Available to Common Excl. Extra. Items -21.467 -41.246 -54.643 -100.217
Income Available to Common Incl. Extra. Items -21.467 -41.246 -54.643 -100.217
Diluted Net Income -21.467 -41.246 -54.643 -100.217
Diluted Weighted Average Shares 43.1386 43.1386 44.4822 47.989
Diluted EPS Excluding Extraordinary Items -0.49763 -0.95613 -1.22842 -2.08833
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.49763 -0.95613 -1.22842 -2.08833
Total Adjustments to Net Income -9.05 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 18.702 18.519 20.336 15.275 9.622
Revenue 18.702 18.519 20.336 15.275 9.622
Total Operating Expense 31.871 43.249 48.973 49.269 46.555
Selling/General/Admin. Expenses, Total 5.909 8.029 10.667 11.74 10.611
Research & Development 25.962 35.22 38.306 37.529 35.944
Operating Income -13.169 -24.73 -28.637 -33.994 -36.933
Interest Income (Expense), Net Non-Operating 0.094 0.07 0.055 0.094 0.249
Net Income Before Taxes -13.075 -24.66 -28.582 -33.9 -36.684
Net Income After Taxes -13.075 -24.66 -28.582 -33.9 -36.684
Net Income Before Extra. Items -13.075 -24.66 -28.582 -33.9 -36.684
Net Income -13.075 -24.66 -28.582 -33.9 -36.684
Total Adjustments to Net Income 0 0 0 0
Income Available to Common Excl. Extra. Items -13.075 -24.66 -28.582 -33.9 -36.684
Income Available to Common Incl. Extra. Items -13.075 -24.66 -28.582 -33.9 -36.684
Diluted Net Income -13.075 -24.66 -28.582 -33.9 -36.684
Diluted Weighted Average Shares 44.6496 45.0942 50.7149 51.4312 51.6511
Diluted EPS Excluding Extraordinary Items -0.29284 -0.54685 -0.56358 -0.65913 -0.71023
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.29284 -0.54685 -0.56358 -0.65913 -0.71023
  • Annual
  • Quarterly
2018 2019 2020 2021
Total Current Assets 41.79 92.845 302.339 451.273
Cash and Short Term Investments 41.26 91.957 296.202 442.418
Cash & Equivalents 41.26 76.015 31.004 47.976
Short Term Investments 0 15.942 265.198 394.442
Total Receivables, Net 0.148 0 1.433 0.135
Prepaid Expenses 0.382 0.888 4.704 8.72
Total Assets 44.231 116.702 487.175 605.905
Property/Plant/Equipment, Total - Net 2.242 22.083 20.686 21.307
Property/Plant/Equipment, Total - Gross 2.466 23.132 22.833 25.223
Accumulated Depreciation, Total -0.224 -1.049 -2.147 -3.916
Other Long Term Assets, Total 0.199 1.774 1.619 8.138
Total Current Liabilities 4.687 34.57 110.617 92.542
Accounts Payable 2.056 3.276 4.368 4.005
Accrued Expenses 2.225 7.175 12.896 25.08
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.302 0.681 0.689 1.138
Other Current Liabilities, Total 0.104 23.438 92.664 62.319
Total Liabilities 5.238 82.028 203.287 146.267
Total Long Term Debt 0.393 1.165 0.604 1.14
Capital Lease Obligations 0.393 1.165 0.604 1.14
Other Liabilities, Total 0.158 46.293 92.066 52.585
Total Equity 38.993 34.674 283.888 459.638
Redeemable Preferred Stock 73.429 109.08
Common Stock 0 0 0.004 0.005
Additional Paid-In Capital 0.774 2.044 412.777 689.275
Retained Earnings (Accumulated Deficit) -35.21 -76.456 -128.765 -228.982
Other Equity, Total 0 0.006 -0.128 -0.66
Total Liabilities & Shareholders’ Equity 44.231 116.702 487.175 605.905
Total Common Shares Outstanding 43.1386 43.1386 44.4822 51.5362
Accounts Receivable - Trade, Net 0.856 0.135
Long Term Investments 162.531 125.187
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 340.791 364.806 543.731 451.273 431.382
Cash and Short Term Investments 333.537 359.107 536.386 442.418 420.812
Cash & Equivalents 53.098 84.903 156.819 47.976 33.733
Short Term Investments 280.439 274.204 379.567 394.442 387.079
Total Receivables, Net 1.734 0.904 1.573 0.135 1.263
Accounts Receivable - Trade, Net 0.878 0.904 1.573 0.135 1.263
Prepaid Expenses 5.52 4.795 5.772 8.72 9.307
Total Assets 464.552 434.386 642.453 605.905 563.06
Property/Plant/Equipment, Total - Net 20.502 21.766 21.724 21.307 21.066
Property/Plant/Equipment, Total - Gross 23.127 24.942 24.951 25.223 25.668
Accumulated Depreciation, Total -2.625 -3.176 -3.227 -3.916 -4.602
Long Term Investments 101.639 45.305 74.692 125.187 102.478
Other Long Term Assets, Total 1.62 2.509 2.306 8.138 8.134
Total Current Liabilities 110.137 108.685 94.493 92.542 88.339
Accounts Payable 8.348 8.177 5.033 4.005 2.567
Accrued Expenses 12.962 16.838 21.105 25.08 22.913
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.64 1.038 1.189 1.138 1.087
Other Current Liabilities, Total 88.187 82.632 67.166 62.319 61.772
Total Liabilities 189.305 176.282 159.318 146.267 134.34
Total Long Term Debt 0.498 1.145 1.347 1.14 0.927
Capital Lease Obligations 0.498 1.145 1.347 1.14 0.927
Other Liabilities, Total 78.67 66.452 63.478 52.585 45.074
Total Equity 275.247 258.104 483.135 459.638 428.72
Common Stock 0.004 0.005 0.005 0.005 0.005
Additional Paid-In Capital 417.096 424.599 678.358 689.275 697.597
Retained Earnings (Accumulated Deficit) -141.84 -166.5 -195.082 -228.982 -265.666
Other Equity, Total -0.013 0 -0.146 -0.66 -3.216
Total Liabilities & Shareholders’ Equity 464.552 434.386 642.453 605.905 563.06
Total Common Shares Outstanding 44.8794 45.3277 51.2565 51.5362 51.6927
  • Annual
  • Quarterly
2018 2019 2020 2021
Net income/Starting Line -21.467 -41.246 -45.593 -100.217
Cash From Operating Activities -17.863 17.905 88.13 -128.946
Cash From Operating Activities 0.205 0.825 1.763 2.397
Non-Cash Items 1.091 1.639 7.093 30.797
Cash Interest Paid 0.015 0.046 0.115 0.158
Changes in Working Capital 2.308 56.687 124.867 -61.923
Cash From Investing Activities -1.356 -16.486 -422.588 -99.835
Capital Expenditures -1.356 -0.532 -9.096 -1.597
Other Investing Cash Flow Items, Total 0 -15.954 -413.492 -98.238
Cash From Financing Activities 52.932 34.911 289.262 250.28
Issuance (Retirement) of Stock, Net 53.227 35.282 276.289 249.18
Issuance (Retirement) of Debt, Net -0.295 -0.371 -0.554 -0.849
Net Change in Cash 33.713 36.33 -45.196 21.499
Financing Cash Flow Items 13.527 1.949
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -13.075 -37.735 -66.317 -100.217 -36.684
Cash From Operating Activities -22.823 -53.334 -90.594 -128.946 -40.295
Cash From Operating Activities 0.485 1.037 1.708 2.397 0.687
Non-Cash Items 4.451 11.409 20.483 30.797 9.048
Cash Interest Paid 0.024 0.054 0.106 0.158 0.046
Changes in Working Capital -14.684 -28.045 -46.468 -61.923 -13.346
Cash From Investing Activities 44.323 105.046 -31.816 -99.835 25.863
Capital Expenditures -0.164 -0.79 -1.096 -1.597 -0.482
Other Investing Cash Flow Items, Total 44.487 105.836 -30.72 -98.238 26.345
Cash From Financing Activities 0.595 2.187 248.226 250.28 0.185
Financing Cash Flow Items -0.397 -0.397 1.95 1.949 0
Issuance (Retirement) of Stock, Net 1.147 2.925 246.969 249.18 0.449
Issuance (Retirement) of Debt, Net -0.155 -0.341 -0.693 -0.849 -0.264
Net Change in Cash 22.095 53.899 125.816 21.499 -14.247
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Atlas Venture Venture Capital 11.6926 6415103 -248923 2022-11-03 LOW
BVF Partners L.P. Hedge Fund 8.553 4692604 0 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 7.4299 4076383 -1148303 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 6.216 3410386 -1624554 2022-09-30 LOW
Vertex Pharmaceuticals Inc Corporation 5.8344 3201049 49928 2022-03-31
Baker Bros. Advisors LP Hedge Fund 5.249 2879825 0 2022-09-30 LOW
Redmile Group, LLC Investment Advisor/Hedge Fund 5.2431 2876637 269507 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.2046 2855478 -14485 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.8946 2685404 -829034 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.8611 2667006 147376 2022-09-30 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 3.9538 2169230 909230 2022-09-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 3.639 1996529 634040 2022-09-30 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 2.734 1500000 500000 2022-09-30 LOW
Wasatch Global Investors Inc Investment Advisor/Hedge Fund 1.933 1060561 489917 2022-09-30 LOW
Rock Springs Capital Management LP Hedge Fund 1.9079 1046743 270864 2022-09-30 LOW
EcoR1 Capital, LLC Hedge Fund 1.451 796093 796093 2022-09-30 MED
Mellon Investments Corporation Investment Advisor/Hedge Fund 1.3139 720875 -28167 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2781 701222 25375 2022-09-30 LOW
Bessemer Venture Partners Venture Capital 1.1226 615895 0 2022-09-30 LOW
Mainolfi (Nello) Individual Investor 1.0242 561931 59732 2022-10-17 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Kymera Therapeutics, Inc. Company profile

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Chemistry. Its clinical stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). Its programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Kymera Therapeutics Inc revenues increased from $34M to $72.8M. Net loss applicable to common stockholders increased 83% to $100.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - increase from $59.8M to $125.3M (expense).

Industry: Biotechnology & Medical Research (NEC)

200 Arsenal Yards Blvd., Suite 230
2Nd Floor
WATERTOWN
MASSACHUSETTS 02472
US

Income Statement

People also watch

BTC/USD

17,004.75 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

XRP/USD

0.39 Price
-0.280% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00373

US100

11,811.10 Price
-1.280% 1D Chg, %
Long position overnight fee -0.0168%
Short position overnight fee 0.0061%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

5.59 Price
-10.150% 1D Chg, %
Long position overnight fee 0.0392%
Short position overnight fee -0.0631%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading